Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for electrolyte balance; dextrose provides caloric support; sodium chloride provides sodium and chloride ions for fluid and electrolyte balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
40-100 mEq potassium chloride intravenously per day, infused at a rate not exceeding 10-20 mEq/hour, with continuous ECG monitoring. Dose and rate depend on serum potassium levels and clinical status.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; potassium is an electrolyte, not a drug with a half-life. Serum potassium half-life depends on distribution and elimination, but is not routinely measured. Potassium is rapidly distributed and excreted with a plasma disappearance half-life of approximately 1-1.5 hours after IV infusion in healthy individuals.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% as potassium ion. Biliary/fecal: <10%.
Category C
Category A/B
Electrolyte
Electrolyte